Evidence map›Paper›PMID 29886840›Full record

ArticleDrug metabolism letters2018

New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation.

Mithat Gunduz, Upendra A Argikar, Amanda L Cirello, Jennifer L Dumouchel

Open access · greenAbstract read
In one paragraph

Article in Drug metabolism letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mithat GunduzNovartis Institutes for BioMedical Research, Inc., Pharmacokinetic Sciences, Global Biotransformation, Cambridge, Watertown, MA 02139, United States.
Upendra A ArgikarNovartis Institutes for BioMedical Research, Inc., Pharmacokinetic Sciences, Global Biotransformation, Cambridge, Watertown, MA 02139, United States.
Amanda L CirelloNovartis Institutes for BioMedical Research, Inc., Pharmacokinetic Sciences, Global Biotransformation, Cambridge, Watertown, MA 02139, United States.
Jennifer L DumouchelNovartis Institutes for BioMedical Research, Inc., Pharmacokinetic Sciences, Global Biotransformation, Cambridge, Watertown, MA 02139, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcyl glucuronides of xenobiotics have been a subject of wide interest from the pharmaceutical industry with respect to biochemical reactivity, hepatic disposition, and enterohepatic circulation. The reactivity and lack of stability of an acyl glucuronide for a clinical candidate could pose major developability concerns. To date, multiple in vitro assays have been published to assess the risk associated with acyl glucuronides. Despite this fact, the translation of these findings to predicting clinical safety remains poor.

methodsIn the present investigation, we aimed to provide simplified in vitro strategy to understand the bioactivation potential of acyl glucuronides of 10 commercial, carboxylic acid containing drugs that have been categorized as "safe," "warning," or "withdrawn" with respect to their marketed use. Acyl migration was measured as a function of the number of peaks observed in LC-MSn analysis. In addition, we carried out reactive intermediate trapping studies with glutathione and methoxylamine to identify the key intermediates in the transacylation bioactivation and glycation pathways, respectively. We also conducted reaction phenotyping with recombinant UDP-glucuronosyltransferase (UGT) Supersomes® to investigate if the formation of acyl glucuronides could be linked to specific UGT isoform(s).

resultsOur results were in line with reported values in the literature. Our assay could be used in discovery research where half-life calculation completely eliminated the need to chemically synthesize the acyl glucuronide standard for risk assessment. We captured our results for risk assessment in a flow chart to simplify the various complex in vitro techniques historically presented.

conclusionWhile the compounds tested from "withdrawn" and "warning category" all formed the glutathione adduct in buffer, none from "safe" category formed the glutathione adduct. In contrast, none of the compounds tested from any category formed methoxylamine conjugate, a reaction with putative aldehyde moiety formed via acyl migration. These results, highly favor the nucleophilic displacement as a cause of the reactivity rather than the acyl migration via aldehyde formation. The workflow presented could also be applied in the discovery setting to triage new chemical entities of interest.

Indexed as

Activation, MetabolicAcylationDrug DiscoveryDrug StabilityGlucuronidesGlucuronosyltransferaseHalf-LifeRisk AssessmentWorkflowXenobioticsGlucuronidesGlucuronosyltransferaseXenobioticsacyl glucuronidesbioactivationglucuronidationmethoxylaminereactivitystabilitythioacyl glutathione.UGT

Identifiers

PMID29886840
PMCPMC6350207
OpenAlexW2892167576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.